Western Equine encephalitis is one of many mosquito-transmitted viral infections that may progress to acute inflammation of the brain parenchyma and meninges. It is caused by an Alphavirus, which is spread primarily by the bite of the Culex and Aedes species of mosquito, or possibly by small, wild mammals. Birds are a reservoir but not a primary vector for the virus. Infections most frequently occur in the summertime in the western United States. Most infections are subclinical but may present with a nonspecific viral syndrome consisting of fever, chills, malaise, and myalgias. While most patients recover spontaneously, some will progress to develop encephalitis. The neuroinvasive disease presents with confusion, somnolence, coma, and occasionally, death. Infants are affected more commonly than adults. Older adults, infants, and young children are more likely to develop severe disease with neurologic involvement. Most patients with mild neurologic symptoms will recover, and adults tend to have a better prognosis than children who are more likely to develop persistent seizures, cognitive and behavioral impairment, and spasticity.
Alphavirus causes Western Equine encephalitis. It is from the Togaviridae family, which includes several viruses that cause other equine encephalitis infections. The virus most closely resembles the Eastern Equine encephalitis virus, which may be a genetic predecessor. The vectors for human transmission are the Culex tarsalis, Culiseta, and Aedes mosquito species. Outbreaks in mules, horses, pheasants, and other birds often accompany human epidemics. Birds serve as amplifying hosts, but no cases of transmission through contact with birds have been reported making them a reservoir but not a vector for infection. There is no aerosolized transmission, but the virus may cross the placenta and be transmitted from mother to fetus. Transmission via infected blood transfusion is unlikely due to low viral loads in most hosts, but possible.
Western Equine encephalitis has been reported in the western United States and Canada. There is a sub-type that has been reported in Argentina with an endemic reservoir in South America.
Most cases have occurred west of the Mississippi River, west of the Rocky Mountains, and in California. The annual incidence of reported infections is highly variable due to periods of inactivity punctuated by outbreaks. Warm weather and heavy rainfall tend to increase vector populations leading to epidemics. Transmission is most common in rural areas. The most significant outbreak occurred in 1941, with over 3000 confirmed human cases. Since 1964 there have been fewer than 700 confirmed cases in the United States. Cases are more commonly reported in males, about twice the rate as females, possibly due to an increased likelihood of outdoor occupations and activities. Transmission is most likely between April and September, with peaks in July and August. During epidemics, a large portion of the population seroconverts but infectivity rates vary with age. Infants are most commonly infected as they have the greatest likelihood of contracting the virus after a mosquito bite. Adults are more commonly targeted by the vector but have lower infectivity rates. However, when they are infected, older adults are more likely to develop more severe, neuroinvasive disease or to die. Infants and very young children are also more likely to develop neurologic manifestations of the disease and seizures. They are more likely than adults to develop permanent disability after infection. Reported infectivity rates are 1:1000 for adults, 1:58 for children aged 1-4, and 1:1 in infants.
The virus is transmitted into the subcutaneous tissue of the host via the bite of an infected mosquito. The virus then begins replication and synthesis of RNA and protein, usually in the local lymph nodes. Viremia ensues, and if the viral load is high enough, the virus may translocate into the central nervous system across the blood-brain barrier resulting in cerebral and meningeal inflammation and necrosis.
Most cases are associated with epidemics in birds or horses. Patients may provide a history of mosquito exposure. The majority of cases are subclinical. There is no associated rash. When symptomatic, infected individuals present with nonspecific, prodromal symptoms of fever, chills, malaise, weakness, and myalgias, typical of many viral and mosquito-borne infections. Most symptomatic cases will still resolve spontaneously within a few days, without any sequelae. Patients may also complain of a headache, neck stiffness, nausea, and vomiting. Progression to neuroinvasive disease is most common in the extremes of age and presents with vertigo, photophobia, confusion, agitation, somnolence, coma, spasticity, and seizures. Neurologic symptoms may develop more quickly in children than in adults. Young children are most likely to have a permanent neurologic disability, and the elderly are most likely to die from complications. Patients who do recover from the acute neurologic disease may complain of fatigue, headaches, and irritability for years.
Because of the similar presentation to multiple other infections, diagnosis is often delayed or difficult. Patients with neurologic symptoms are evaluated with neuroimaging studies such as computed tomography (CT) or magnetic resonance imaging (MRI). Inflammatory changes may be seen in the thalamus or basal ganglia but are nonspecific and may be found with encephalitis due to many causes. A lumbar puncture may show elevated opening pressure, protein, and cell count with a lymphocytic predominance. These findings are also non-specific and common in many other forms of viral or inflammatory meningitis and encephalitis.
Isolation of the virus from serum or CSF is difficult. In infected patients, IgG antibody is generally detectable within 1 to 3 weeks after infection and peaks at 1 to 2 months. IgG indicates exposure to the virus and, depending on the titer, suggests recent infection. The presence of IgM antibody correlates with acute infection and can be detected within 1 to 3 weeks from the onset of symptoms. The test for Western equine encephalitis cross-reacts with St. Louis encephalitis virus, making distinguishing between the two infections difficult.
There is currently no vaccine to prevent Western Equine encephalitis, but there are clinical trials underway by the United States (US) Army Medical Research and Material Command. Nor is there any effective antiviral therapy, so care is largely supportive and centered around the management of complications. Patients with encephalitis may require mechanical ventilation and management of increased intracranial pressure. Seizures are common with neuroinvasive disease and may require anticonvulsants. Patients with seizures are more likely to develop a lifetime seizure disorder.
Since there is no effective treatment or vaccine, prevention is critical. This is best accomplished by avoiding mosquito bites entirely. Even very short periods of outdoor exposure can result in bites, so proper protective clothing should be worn. These protective measures include long sleeves, long pants, socks, and closed-toe shoes. Pant legs can be tucked into socks to prevent bites to exposed ankles. Transmission is common during the warmer months, and mosquitoes may bite through very thin clothing, so treating clothing with repellents containing permethrin, DEET, oil of lemon eucalyptus, or other EPA-registered insect repellants will reduce this risk. Permethrin should not be applied directly to the skin but, when applied to clothing, provides protection even after the clothing is washed. Transmission is most frequent when mosquitoes feed, between dawn and dusk, so outdoor activities during this period should be avoided. Travelers should sleep in air-conditioned spaces or use mosquito nets or screens to prevent bites during sleep. Standing water is a breeding ground for mosquitoes, so flower pots, buckets, and other containers should be drained. Children’s wading pools should be emptied and stored on their sides, and tire swings should have holes drilled into the bottom to allow trapped water to drain.
The differential diagnosis of Western Equine encephalitis is broad and makes a careful travel history important. It includes:
Patients who contract the virus but do not develop neurologic symptoms will fully recover, as do most adults with the only mild neurologic disease. Children who develop neurologic disease have a 30% chance of having a permanent disability such as seizures, spasticity, and cognitive or behavioral disorders. As compared with Eastern equine encephalitis for which mortality approaches 70%, mortality is low, only around 4%. Most fatalities occur in elderly patients.
The diagnosis and management of WEE are with an interprofessional team that includes a neurologist, internist, infectious disease expert, primary care provider, and nurse practitioner. The diagnosis of WEE is not easy, and there is no specific treatment. The majority of patients are managed with supportive care, and symptoms are treated with pharmacological therapy.
The primary care provider, nurse practitioner, and nurse play a vital role in the prevention of WEE. The key is to educate the patient against mosquito bites. These protective measures include wearing long sleeves, long pants, socks, and closed-toe shoes. Pant legs can be tucked into socks to prevent bites to exposed ankles. One may also use DEET to repel mosquitoes. Travelers should sleep in air-conditioned spaces or use mosquito nets or screens to prevent bites during sleep. Standing water is a breeding ground for mosquitoes, so flower pots, buckets, and other containers should be drained. When symptoms develop, prompt treatment should be sought. Critical care and neuroscience nurses may be involved in the acute care of symptomatic patients. Rehabilitation nurses assist in cases where patients have long term complications. The nurses monitor the patients and provide updates on status to the rest of the team. [Level 5]
|||Carey BD,Bakovic A,Callahan V,Narayanan A,Kehn-Hall K, New World alphavirus protein interactomes from a therapeutic perspective. Antiviral research. 2019 Mar; [PubMed PMID: 30695702]|
|||Ferreira-Ramos AS,Li C,Eydoux C,Contreras JM,Morice C,Quérat G,Gigante A,Pérez Pérez MJ,Jung ML,Canard B,Guillemot JC,Decroly E,Coutard B, Approved drugs screening against the nsP1 capping enzyme of Venezuelan equine encephalitis virus using an immuno-based assay. Antiviral research. 2019 Mar; [PubMed PMID: 30639438]|
|||Robb LL,Hartman DA,Rice L,deMaria J,Bergren NA,Borland EM,Kading RC, Continued Evidence of Decline in the Enzootic Activity of Western Equine Encephalitis Virus in Colorado. Journal of medical entomology. 2018 Dec 6; [PubMed PMID: 30535264]|
|||Kumar B,Manuja A,Gulati BR,Virmani N,Tripathi BN, Zoonotic Viral Diseases of Equines and Their Impact on Human and Animal Health. The open virology journal. 2018; [PubMed PMID: 30288197]|
|||Baxter VK,Heise MT, Genetic control of alphavirus pathogenesis. Mammalian genome : official journal of the International Mammalian Genome Society. 2018 Aug; [PubMed PMID: 30151711]|
|||Chapman GE,Baylis M,Archer D,Daly JM, The challenges posed by equine arboviruses. Equine veterinary journal. 2018 Jul; [PubMed PMID: 29517814]|
|||Lundberg L,Carey B,Kehn-Hall K, Venezuelan Equine Encephalitis Virus Capsid-The Clever Caper. Viruses. 2017 Sep 29; [PubMed PMID: 28961161]|
|||Ronca SE,Dineley KT,Paessler S, Neurological Sequelae Resulting from Encephalitic Alphavirus Infection. Frontiers in microbiology. 2016; [PubMed PMID: 27379085]|
|||Aréchiga-Ceballos N,Aguilar-Setién A, Alphaviral equine encephalomyelitis (Eastern, Western and Venezuelan). Revue scientifique et technique (International Office of Epizootics). 2015 Aug; [PubMed PMID: 26601451]|
|||Barker CM,Reisen WK,Kramer VL, California state Mosquito-Borne Virus Surveillance and Response Plan: a retrospective evaluation using conditional simulations. The American journal of tropical medicine and hygiene. 2003 May; [PubMed PMID: 12812335]|
|||West Nile virus disease and other arboviral diseases--United States, 2010. MMWR. Morbidity and mortality weekly report. 2011 Aug 5; [PubMed PMID: 21814163]|